{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/prescribing-information/fluconazole-oral/","result":{"pageContext":{"chapter":{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral","depth":2,"htmlHeader":"<!-- begin field 53ea2a07-1996-4537-b054-256b9ba68109 --><h2>Fluconazole - oral</h2><!-- end field 53ea2a07-1996-4537-b054-256b9ba68109 -->","summary":"","htmlStringContent":"<!-- begin item f147b992-b7ca-460c-a22d-dc8c6a54f2ef --><!-- end item f147b992-b7ca-460c-a22d-dc8c6a54f2ef -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"800e543f-aa34-535b-982f-b67228787534","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d4845d14-1b52-569e-b9f1-d3ab14fa2321","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ed0a5dea-44b1-4af5-8912-a7560159c798 --><h3>What are the contraindications and cautions for oral fluconazole?</h3><!-- end field ed0a5dea-44b1-4af5-8912-a7560159c798 -->","summary":"","htmlStringContent":"<!-- begin item 3ca0b12d-45aa-43c3-a8e3-a7560159c783 --><!-- begin field 693cc119-591a-447c-94be-a7560159c798 --><ul><li><strong>Do not prescribe:</strong><ul><li><strong>Oral fluconazole to:</strong><ul><li>People with acute porphyria.</li><li>Pregnant women.</li><li>People taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>High or repeated doses of oral fluconazole to:</strong><ul><li>Breastfeeding women.</li></ul></li></ul></li><li><strong>Prescribe oral fluconazole with caution to people:</strong><ul><li>At risk of QT interval prolongation — this includes people with cardiomyopathy, sinus bradycardia, arrhythmias, hypokalaemia, hypomagnesaemia, hypocalcaemia, and those taking other drugs known to cause QT interval prolongation (such as tricyclic antidepressants, antipsychotics, and antiarrhythmics).</li><li>With hepatic impairment or taking concurrent hepatotoxic drugs, due to the risk of hepatic necrosis — discontinue treatment if signs or symptoms of hepatic disease develop (such as severe abdominal pain, jaundice, or weakness). </li><li>With renal impairment (estimated glomerular filtration rate [eGFR] less than 50 mL/min/1.73m<sup>2</sup>) — use the usual initial dose then halve any subsequent doses.</li><li>Who are taking <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/#drug-interactions\">certain drugs</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]</p><!-- end field 693cc119-591a-447c-94be-a7560159c798 --><!-- end item 3ca0b12d-45aa-43c3-a8e3-a7560159c783 -->","subChapters":[]},{"id":"585512f4-8b8b-5234-98d1-e9ec69b6e765","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4224b8a2-32e3-44ea-b48c-a7560159dbff --><h3>What adverse effects are associated with oral fluconazole?</h3><!-- end field 4224b8a2-32e3-44ea-b48c-a7560159dbff -->","summary":"","htmlStringContent":"<!-- begin item b79a1c59-38a2-459e-8d34-a7560159dc23 --><!-- begin field 05eb09f3-b59a-4216-83aa-a7560159dbff --><ul><li><strong>Adverse effects </strong><strong>of oral fluconazole include:</strong><ul><li><strong>Common or very common</strong><ul><li>Abdominal discomfort, diarrhoea, nausea, and flatulence.</li><li>Headache.</li><li>Rash — discontinue treatment if the infection becomes invasive or systemic.</li></ul></li><li><strong>Uncommon</strong><ul><li>Alopecia.</li><li>Adrenal insufficiency.</li><li>Dizziness.</li><li>Vomiting, dyspepsia, and taste disturbance.</li><li>Hepatic disorders.</li><li>Hyperlipidaemia.</li><li>Seizures.</li><li>Pruritus, anaphylaxis, angioedema (in children), hypersensitivity reactions (in adults), Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul></li><li><strong>Frequency unknown</strong><ul><li>Hypokalaemia.</li><li>Leucopenia and thrombocytopenia.</li></ul></li></ul></li><li>Severe cutaneous reactions are more likely in people with AIDS.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]</p><!-- end field 05eb09f3-b59a-4216-83aa-a7560159dbff --><!-- end item b79a1c59-38a2-459e-8d34-a7560159dc23 -->","subChapters":[]},{"id":"15fb0253-4f2c-5b73-ac7c-b9b9fe09769e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a89332f1-82fa-4ee1-b51c-a7560159ee36 --><h3>What drug interactions are associated with oral fluconazole?</h3><!-- end field a89332f1-82fa-4ee1-b51c-a7560159ee36 -->","summary":"","htmlStringContent":"<!-- begin item 6cf79db9-054e-4077-ab33-a7560159ee53 --><!-- begin field 46c8f121-d543-4893-b207-a7560159ee36 --><ul><li><strong>Fluconazole inhibits the metabolism of drugs metabolized by the cytochrome P450 enzymes CYP2C9 (potently), CYP3A4 (moderately), and CYP2C19</strong><strong>. This may result in a higher and/or prolonged action of these drugs, including adverse effects. </strong>The enzyme-inhibiting effect of fluconazole persists 4–5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole. <ul><li><strong>The following drugs are contraindicated (or should be avoided) during treatment with fluconazole:</strong><ul><li>Ergotamine — there is an increased risk of ergotism.</li><li>Erythromycin — concurrent use with fluconazole has the potential to increase the risk of cardiotoxicity (prolonged QT interval and Torsades de Pointes) and consequently sudden heart death.</li><li>Pimozide — concurrent use with fluconazole may lead to QT prolongation and rare occurrences of Torsade de Pointes.</li><li>Quetiapine.</li><li>Reboxetine.</li></ul></li><li><strong>Concurrent treatment with f</strong><strong>luconazole and the following drugs </strong><strong>should be done with caution </strong>(concurrent use should be monitored; dose adjustments may be indicated):<ul><li>Aminophylline and theophylline.</li><li>Avanafil.</li><li>Ciclosporin.</li><li>Coumarins, such as warfarin. </li><li>Diazepam (risk of prolonged sedation).</li><li>Fentanyl.</li><li>Midazolam (risk of prolonged sedation).</li><li>Phenytoin.</li><li>Rifabutin (increased risk of uveitis).</li><li>Statins — the risk of myopathy and rhabdomyolysis increases when fluconazole is given with statins metabolized through CYP3A4 (atorvastatin and simvastatin) or through CYP2C9 (fluvastatin). If concurrent treatment is necessary, monitor for symptoms of myopathy and rhabdomyolysis, and monitor creatine kinase. Discontinue the statin if a marked increase in creatine kinase is observed or if myopathy/rhabdomyolysis is diagnosed or suspected.</li><li>Sulfonylureas (such as gliclazide and glipizide) — if concurrent use is indicated, advise the person to seek medical advice if they have symptoms of hypoglycaemia (for example nervousness, sweating, and/or trembling).</li><li>Tacrolimus and sirolimus.</li><li>Tretinoin — fluconazole possibly increases the risk of tretinoin toxicity.</li><li>Zidovudine — fluconazole increases the risk of zidovudine toxicity. </li></ul></li></ul></li><li><strong>Other possible drug interactions of fluconazole include:</strong><ul><li>Clopidogrel — fluconazole possibly reduces the antiplatelet effect of clopidogrel.</li><li>Hydrochlorothiazide — the plasma levels of fluconazole may be increased by 40%; however, no adjustment in dosage of fluconazole is required. </li><li>Rifampicin — metabolism of fluconazole may be accelerated by rifampicin, leading to reduced plasma concentrations.</li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions of fluconazole</strong><strong>, </strong>see the <a href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\" data-hyperlink-id=\"5d1bd39e-1a5d-4822-a304-a98f017ff9da\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"eadda68c-df0e-46e1-aaa7-a98f017ffaca\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]</p><!-- end field 46c8f121-d543-4893-b207-a7560159ee36 --><!-- end item 6cf79db9-054e-4077-ab33-a7560159ee53 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}